What is ABOS stock price today?

ABOS (Acumen Pharmaceuticals Inc) stock is trading at $2.17 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ABOS stock going up or down today?

ABOS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ABOS stock now?

The decision to buy ABOS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ABOS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ABOS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ABOS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ABOS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ABOS's P/E ratio?

P/E ratio data for ABOS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ABOS's market cap?

ABOS (Acumen Pharmaceuticals Inc) has a market capitalization of $0.17 billion, making it a small-cap stock.

What is ABOS's price to book ratio?

ABOS trades at a price-to-book (P/B) ratio of 2.08, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ABOS pay dividends?

ABOS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ABOS's dividend yield?

ABOS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ABOS stock a good long-term investment?

ABOS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ABOS's revenue growth rate?

Revenue growth data for ABOS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ABOS are available on our dashboard with complete income statement analysis.

What are the risks of investing in ABOS?

Key risks for ABOS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ABOS compare to its competitors?

Compare ABOS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ABOS's performance and positioning.

What is ABOS's stock price target for 2026?

Our AI model provides price targets for ABOS based on fundamental analysis: Bull case $2.82 (+30%), Base case $2.50 (+15%), Bear case $1.95 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ABOS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ABOS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ABOS's next earnings report?

ABOS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ABOS - Acumen Pharmaceuticals Inc

NYSE * Healthcare * Biotechnology

$2.17

$-0.12 (-5.24%)

About Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Price Chart

Loading chart...

ABOS Key Statistics

Market Cap

$165.40M

P/B Ratio

2.08

EPS

$-1.85

Employees

How ABOS Compares to Peers

ABOS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ABOS(This stock)	$165.40M	N/A	0%	0.0%	-
AMGNAmgen Inc	$186.52B	24.0	0%	0.2%	vs AMGN
GILDGilead Sciences	$160.39B	17.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.12B	26.2	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$66.84B	15.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$29.00B	21.1	0%	0.1%	vs BIIB

Acumen Pharmaceuticals Inc Company Information

Headquarters: 1210-1220 Washington St., Newton, MA, United States, 02465, undefined
Website: acumenpharm.com
Sector: Healthcare
Industry: Biotechnology

ABOS - Acumen Pharmaceuticals Inc

About Acumen Pharmaceuticals Inc

Price Chart

ABOS Key Statistics

How ABOS Compares to Peers

Acumen Pharmaceuticals Inc Company Information

ABOS Lician Score

ABOS Financial Snowflake

Upcoming Events for ABOS